Hemorrhagic Complications of Anticoagulant Therapy

Levine, Mark; Hirsh, Jack

doi:10.1055/s-2007-1003533

Cited by 106 publications

(43 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic range for heparin reflects a minimum adequate level to prevent extension or recurrence and a maximum level to decrease the risk of bleeding (1,26,27). Unfortunately, different APTT reagents have widely varying sensitivities to heparin that significantly affect the therapeutic range (28).…”

Section: Discussionmentioning

confidence: 99%

Heparin Therapy in Pediatric Patients: A Prospective Cohort Study

et al. 1994

View full text Add to dashboard Cite

ABSTRACT. Current guidelines for heparin therapy in pediatric patients have been extrapolated from trials in adult patients without rigorous evaluation of efficacy and safety. We prospectively monitored consecutive pediatric patients receiving systemic doses of heparin over 10 mo at one institution using a predetermined nomogram to monitor maintenance therapy. Sixty-five consecutive children; 38 males and 27 females, received systemic doses of heparin.Thirty children had deep venous thrombosis and/or pulmonary embolism; l l had arterial thrombi, most frequently after diagnostic angiography; and the remaining 24 received heparin prophylactically, for congenital heart disease. Twenty-nine (45%) of the 65 patients were less than 1 y of age and 22 (34%) were 10 y or older. Congenital heart disease was the predominant diagnosis under 1 y and deep venous thrombosis in older children. After a bolus dose of 50 U/kg, 39% of children (n = 30) achieved a minimal level activated partial thromboplastin time ( A m ) . Sixty-eight percent of children achieved a minimal level A P l T by 24 h and 81% by 48 h. For all 65 children, A P l T values were within the therapeutic range 43% of the time. APTT values outside the therapeutic range were twice as likely to be low as high. The average amount of heparin required to maintain therapeutic A P l T values for children was 22 UFglh: 28 U/kg/h for infants

show abstract

Section: Discussionmentioning
confidence: 99%

Heparin Therapy in Pediatric Patients: A Prospective Cohort Study
Andrew
¹
,
Marzinotto
²
,
Massicotte
³

et al. 1994
Pediatr Res
202
7
146
3
View full text Add to dashboard Cite

show abstract

“…Hemorrhagic complications of heparin anticoagulant therapy remain a significant clinical problem (1)(2)(3). Although some studies suggest that bleeding complications may be more common when the anticoagulant effects ofheparin are excessive (as judged by coagulation assays), serious bleeding may occur in spite of satisfactory monitoring and control (2).…”

Section: Introductionmentioning
confidence: 99%

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
Sobel
¹
,
McNeill
²
,
Carlson³
et al. 1991
J. Clin. Invest.
199
2
83
0
View full text Add to dashboard Cite

show abstract

“…Table 1 summarises the demographic characteristics of the studied patient groups. Six patients were lost to follow up due to geographical distance [4] or non compliance with CCD [2] leaving thirty-eight patients in Group 1 and thirty-nine patients in Group 2 .…”

Section: Methodsmentioning
confidence: 99%

“…Other complications associated with anti-coagulation use which have the potential to cause considerable morbidity and mortality include injection site erythema, hematoma, Heparin Induced Thrombocytopenia (HIT) and allergy. These effects are amplified when treatment extends beyond fourteen days [4,5], thus alternative approaches to anti-coagulation regimens in the peri-operative period are required.…”

Section: Introductionmentioning
confidence: 99%

Combined Short Course Low Molecular Weight Heparin and Calf Compression Therapy in Prevention of Deep Vein Thrombosis after Total Knee Replacement: A Randomized Prospective Study
Ramakrishna¹,
Gupta²,
Sarathy³
et al. 2013
J Hematol Thromb Dis
1
0
0
0
View full text Add to dashboard Cite

Background and aims: Anti-coagulation is an important component of post-operative Venous-Thombo-Embolic (VTE) prophylaxis but can be associated with significant complications including hemorrhage. Current guidelines favour anti-coagulation for ≥ 14 days with little evidence evaluating the efficacy of anticoagulation <14 days. Our study hypothesizes that short course Low-Molecular-Weight-Heparin (LMWH for 5-7 days) in combination with Calf Compression Device (CCD) is equally effective as standard therapy LMWH (14 days) in preventing VTE and related events amongst patients undergoing Total-Knee-Replacement (TKR).

show abstract

Hemorrhagic Complications of Anticoagulant Therapy

Cited by 106 publications

References 44 publications

Heparin Therapy in Pediatric Patients: A Prospective Cohort Study

Heparin Therapy in Pediatric Patients: A Prospective Cohort Study

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

Combined Short Course Low Molecular Weight Heparin and Calf Compression Therapy in Prevention of Deep Vein Thrombosis after Total Knee Replacement: A Randomized Prospective Study

Contact Info

Product

Resources

About